News & Updates
– Over 900 patients with diabetic macular edema enrolled worldwide Excerpt from the Press Release: PALO ALTO, Calif., Feb. 3, 2022 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its GLEAM and GLIMMER Phase 3…
Read More
–The method could eventually lead to more personalized medicine approaches as well as properly diagnose patients with multiple disorders — Excerpt from the Press Release: PHILADELPHIA, Feb. 1, 2022 /PRNewswire/ –Minority populations have been historically under-represented in existing studies addressing how genetic variations may contribute to a variety of disorders. A new study from researchers at Children’s Hospital…
Read More
Excerpt from the Press Release: PHILADELPHIA — (Feb. 1, 2022) — The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less effective against some variants. Now scientists at The Wistar Institute have developed a more targeted vaccine that, in animal studies, shows stronger,…
Read More
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Minerva Biotechnologies Corporation announced today that its trial of huMNC2-CAR44 T cells (NCT04020575) has now opened at City of Hope, Duarte, California. This is a first-in-human trial targeting the tumor-associated form of MUC1, called MUC1* (muk 1 star). MUC1* is the transmembrane cleavage product that is a growth…
Read More
Data show bemnifosbuvir’s unique mechanism of action increases barrier for emergence of resistance, making it an ideal candidate for treatment of COVID-19 and for combination therapy Excerpt from the Press Release: BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir…
Read More
– Multicenter Phase 1 study to evaluate IO-202 as monotherapy and in combination with an anti-PD-1 Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational…
Read More
Excerpt from the Press Release: Atara Biotherapeutics, a California-based developer of cell therapies, will sell a large factory it built there to a contract manufacturing division of Japan’s Fujifilm, announcing Wednesday a $100 million deal with Fujifilm Diosynth Biotechnologies. The facility, which encompasses 90,000 square feet in Thousand Oaks, California, was once a key component of Atara’s…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI). The Phase 3 real-world evidence study will evaluate the safety, efficacy, and cost-effectiveness of Cognito’s therapeutic platform in MCI…
Read More
Phase 2 study of Omicron-specific booster candidate (mRNA-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mRNA-1273 and another including participants who received the two-dose primary series and a 50 µg booster dose of mRNA-1273 Omicron neutralization six months after the third 50 µg dose of mRNA-1273 declined, but remained…
Read More
– Israel Institute for Biological Research files initial scientific results of BriLife vaccine effectiveness in producing neutralizing antibody against Omicron Variant – Neutralizing antibody level against Omicron is approximately 1/3 of the comparable antibody level against the original Corona Virus – Ten of 13 tested patients vaccinated during phase 2 trials demonstrated measurable level of…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?